Tuberous Sclerosis Complex–Associated Angiomyolipomas: Focus on mTOR Inhibition
Authors:
- Klemens BuddeKBKlemens Budde
- Jens GaedekeJGJens Gaedeke
- 1 February 2012
- journal article
- review article
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 59 (2) , 276-283
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous SclerosisNew England Journal of Medicine, 2010
- The tuberous sclerosis complexAnnals of the New York Academy of Sciences, 2010
- Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascadeJournal of Clinical Investigation, 2010
- The evolutionarily conserved TSC/Rheb pathway activates Notch in tuberous sclerosis complex and Drosophila external sensory organ developmentJournal of Clinical Investigation, 2010
- Regression of Subependymal Giant Cell Astrocytoma With Rapamycin in Tuberous Sclerosis ComplexJournal of Child Neurology, 2008
- Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or LymphangioleiomyomatosisNew England Journal of Medicine, 2008
- An epidemiological study of renal pathology in tuberous sclerosis complexBJU International, 2004
- Tuberous sclerosis complex and its foundersJournal of Neurology, Neurosurgery & Psychiatry, 2004
- Genotype-phenotype correlations in tuberous sclerosisJournal of Medical Genetics, 2000
- Causes of Death in Patients With Tuberous SclerosisMayo Clinic Proceedings, 1991